Alireza Najafian1, Salem Noureldine2, Faris Azar1, Chady Atallah1, Gina Trinh2, Eric B Schneider1, Ralph P Tufano2, Martha A Zeiger1,3,4. 1. 1 Endocrine Surgery, Department of Surgery, The Johns Hopkins University School of Medicine , Baltimore, Maryland. 2. 2 Division of Head and Neck Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine , Baltimore, Maryland. 3. 3 Department of Oncology, The Johns Hopkins University School of Medicine , Baltimore, Maryland. 4. 4 Department of Cellular and Molecular Medicine, The Johns Hopkins University School of Medicine , Baltimore, Maryland.
Abstract
BACKGROUND: Molecular markers associated with thyroid malignancy are increasingly being used as differential diagnostic tools for thyroid nodules. However, little has been reported recently regarding the prevalence of these markers in benign lesions. The literature was systematically reviewed to examine studies that reported on the prevalence of these markers in benign thyroid lesions. METHODS: Appropriate studies published between January 1, 2000, and April 30, 2015, and cataloged in PubMed, Embase, Cochrane, Scopus, and Web of Science databases were searched for by combining different keywords for "thyroid tumor" with both general and specific keywords for "molecular marker" by using "AND" as the Boolean operator. All studies meeting criteria that reported the prevalence of RAS mutations, and RET/PTC and PAX8/PPAR-gamma chromosomal rearrangements in benign thyroid lesions were included for study. RESULTS: A total of 64 articles (including 8162 patients, of whom 42.5% had benign lesions) that met all the study criteria were systematically reviewed and abstracted. Among 35 studies examining RAS mutations, the reported prevalence of RAS mutation in benign lesions ranged from 0% to 48%. In 38 studies examining RET/PTC rearrangements, the prevalence in benign lesions ranged from 0% to 68%. PAX8/PPAR-gamma rearrangements were examined in 27 studies, with the prevalence in benign lesions ranging from 0% to 55%. CONCLUSION: The presence of these biomarkers and the tremendous variation in reports of their prevalence in benign lesions suggests the need for caution when including these markers in diagnostic decisions. Further understanding of the importance of these markers, as well as newly discovered markers of thyroid malignancy, may be required in order to avoid overtreatment of patients with benign thyroid tumors.
BACKGROUND: Molecular markers associated with thyroid malignancy are increasingly being used as differential diagnostic tools for thyroid nodules. However, little has been reported recently regarding the prevalence of these markers in benign lesions. The literature was systematically reviewed to examine studies that reported on the prevalence of these markers in benign thyroid lesions. METHODS: Appropriate studies published between January 1, 2000, and April 30, 2015, and cataloged in PubMed, Embase, Cochrane, Scopus, and Web of Science databases were searched for by combining different keywords for "thyroid tumor" with both general and specific keywords for "molecular marker" by using "AND" as the Boolean operator. All studies meeting criteria that reported the prevalence of RAS mutations, and RET/PTC and PAX8/PPAR-gamma chromosomal rearrangements in benign thyroid lesions were included for study. RESULTS: A total of 64 articles (including 8162 patients, of whom 42.5% had benign lesions) that met all the study criteria were systematically reviewed and abstracted. Among 35 studies examining RAS mutations, the reported prevalence of RAS mutation in benign lesions ranged from 0% to 48%. In 38 studies examining RET/PTC rearrangements, the prevalence in benign lesions ranged from 0% to 68%. PAX8/PPAR-gamma rearrangements were examined in 27 studies, with the prevalence in benign lesions ranging from 0% to 55%. CONCLUSION: The presence of these biomarkers and the tremendous variation in reports of their prevalence in benign lesions suggests the need for caution when including these markers in diagnostic decisions. Further understanding of the importance of these markers, as well as newly discovered markers of thyroid malignancy, may be required in order to avoid overtreatment of patients with benign thyroid tumors.
Authors: M Pastoricchio; A Cubisino; A Lanzaro; M Troian; F Zanconati; S Bernardi; B Fabris; N de Manzini; C Dobrinja Journal: Int J Endocrinol Date: 2020-04-14 Impact factor: 3.257
Authors: Zeyad T Sahli; Philip W Smith; Christopher B Umbricht; Martha A Zeiger Journal: Front Endocrinol (Lausanne) Date: 2018-04-18 Impact factor: 5.555
Authors: Joshua R Krasner; Nourah Alyouha; Marc Pusztaszeri; Veronique-Isabelle Forest; Michael P Hier; Galit Avior; Richard J Payne Journal: J Otolaryngol Head Neck Surg Date: 2019-10-17
Authors: Ana Carolina de Jesus Paniza; Thais Biude Mendes; Matheus Duarte Borges Viana; Débora Mota Dias Thomaz; Paula B O Chiappini; Gabriel A Colozza-Gama; Susan Chow Lindsey; Marcos Brasilino de Carvalho; Venâncio Avancini Ferreira Alves; Otavio Curioni; André Uchimura Bastos; Janete Maria Cerutti Journal: Endocr Connect Date: 2019-11 Impact factor: 3.335